论文部分内容阅读
目的观察厄贝沙坦氢氯噻嗪片对原发性高血压患者血清肿瘤坏死因子-α(TNF-α)和白细胞介素6(IL-6)水平的影响。方法 72例原发性高血压患者随机分为对照组和治疗组,每组36例,对照组服用硝苯地平缓释片,治疗组服用厄贝沙坦氢氯噻嗪片片,治疗8周,分别于治疗前后检测患者血清中细胞因子TNF-α和IL-6水平。结果治疗前,两组患者血压和血清TNF-α、IL-6水平比较,差异无统计学意义(P>0.05)。治疗后,治疗组患者血压和血清TNF-α、IL-6水平均明显低于对照组,差异有统计学意义(P<0.05或P<0.01)。结论厄贝沙坦氢氯噻嗪片能够降低原发性高血压患者血清TNF-α和IL-6水平、抑制炎症反应。
Objective To observe the effects of irbesartan hydrochloride hydrochlorothiazide tablets on serum levels of tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) in patients with essential hypertension. Methods Seventy-two patients with essential hypertension were randomly divided into control group and treatment group, 36 cases in each group. The control group was treated with nifedipine sustained-release tablets. The treatment group took irbesartan hydrochlorothiazide tablets for 8 weeks. Serum levels of cytokines TNF-α and IL-6 were measured before and after treatment. Results Before treatment, there was no significant difference in blood pressure, serum TNF-α and IL-6 levels between the two groups (P> 0.05). After treatment, the levels of blood pressure and serum TNF-α and IL-6 in the treatment group were significantly lower than those in the control group, with statistical significance (P <0.05 or P <0.01). Conclusion Irbesartan hydrochlorothiazide tablet can reduce the level of serum TNF-α and IL-6 in patients with essential hypertension and inhibit the inflammatory reaction.